We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

This study has been withdrawn prior to enrollment.
(Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell production.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00866346
First Posted: March 20, 2009
Last Update Posted: March 4, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: No date given
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)